RUA Life Sciences PLC
Company Profile
Business description
RUA Life Sciences PLC is a biomedical polymer technology, components, and medical device company. The company's principal activities comprise exploiting the value of its IP and know-how, medical device contract manufacturing, and development of cardiovascular devices. Its business segments are Royalty and License Income (Biomaterials), Contract Manufacture, Product Development (Vascular), and Product Innovation (Structural Heart). It derives the majority of its revenue from the Contract Manufacture segment. Geographically, it derives the majority of its revenue from the USA and has a presence in Switzerland, Italy, the UK, and Israel.
Contact
2 Drummond Crescent
Ayrshire
Scotland
IrvineKA11 5AN
GBRT: +44 1294317073
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 March 2025
Employees
40
Stocks News & Analysis
stocks
16 ASX stocks to buy and hold forever, revisited
stocks
This ASX200 reject could be a contrarian buying opportunity
stocks
A 15 step checklist from Buffett's forgotten inspiration
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,982.40 | 121.00 | -1.49% |
| CAC 40 | 7,941.91 | 105.69 | -1.31% |
| DAX 40 | 22,328.77 | 292.18 | -1.29% |
| Dow JONES (US) | 41,433.48 | 478.23 | -1.14% |
| FTSE 100 | 8,495.99 | 104.23 | -1.21% |
| HKSE | 23,721.52 | 60.62 | -0.25% |
| NASDAQ | 17,436.10 | 32.22 | -0.18% |
| Nikkei 225 | 36,898.83 | 105.72 | 0.29% |
| NZX 50 Index | 12,273.83 | 137.14 | -1.10% |
| S&P 500 | 5,572.07 | 42.49 | -0.76% |
| S&P/ASX 200 | 7,763.40 | 126.70 | -1.61% |
| SSE Composite Index | 3,374.08 | 5.75 | -0.17% |